Moderna, Inc.
MRNA
$59.81
$0.641.08%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -17.54% | 309.30% | -31.13% | -46.54% | -38.04% |
| Total Other Revenue | 82.14% | 68.18% | 14.29% | 2.38% | -50.88% |
| Total Revenue | 2.11% | 260.19% | -29.81% | -45.44% | -41.08% |
| Cost of Revenue | -9.89% | -23.26% | -34.07% | -38.95% | -38.70% |
| Gross Profit | 12.41% | 59.79% | 38.66% | -96.21% | 38.17% |
| SG&A Expenses | -6.09% | -18.40% | -12.25% | -4.63% | -14.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.06% | -22.37% | -30.61% | -33.95% | -34.60% |
| Operating Income | 10.80% | 51.43% | 31.22% | -271.43% | 33.46% |
| Income Before Tax | 6.23% | -38.38% | 32.52% | -990.48% | 36.04% |
| Income Tax Expenses | 114.29% | 28.57% | 142.19% | 62.50% | -- |
| Earnings from Continuing Operations | 5.21% | -38.31% | 26.25% | -1,638.46% | 35.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.21% | -38.31% | 26.25% | -1,638.46% | 35.50% |
| EBIT | 10.80% | 51.43% | 31.22% | -271.43% | 33.46% |
| EBITDA | 12.24% | 55.39% | 33.39% | -1,055.56% | 35.70% |
| EPS Basic | 7.60% | -35.16% | 27.57% | -1,617.16% | 36.16% |
| Normalized Basic EPS | 9.31% | 53.54% | 33.38% | -728.54% | 35.54% |
| EPS Diluted | 7.60% | -35.16% | 27.65% | -1,809.33% | 36.16% |
| Normalized Diluted EPS | 9.31% | 53.54% | 33.38% | -751.28% | 35.54% |
| Average Basic Shares Outstanding | 2.58% | 2.33% | 1.82% | 1.30% | 1.04% |
| Average Diluted Shares Outstanding | 2.58% | 2.33% | 1.82% | -2.26% | 1.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |